Tag Archives: CEO & Investor Conference

Boston in the Spring Time is Even More Lovely with BIO

BIO will debut a new conference in Boston April 22-23.  The National Venture Conference will draw early-stage, private biotech companies and healthcare venture partners.  I hope to see you there, but in the meantime, check out http://bnvc.bio.org for more details in the coming months.

Events  |  Leave a comment  |  Email This Post
Tags:

Biotech World to Descend on San Diego

The 2008 BIO International Convention is the place to be for anyone covering the life sciences, investments and policy.  If you have attended in the past, you’ll notice a few changes – the day pattern will be Tuesday through Friday, come into town early though for the golf outing. I’ll be dragging my Patti Berg’s to California, should be fun. Check out the new program tracks – Biomarkers, Growing the Biotech Workforce, and International Case Studies.  Join Read More >

Events  |  Leave a comment  |  Email This Post
Tags:

From the Hill to the Street: Examining Policy Issues in Biotech

Without a supportive legislative and regulatory environment, biotech companies cannot raise the funds necessary to get a product to market.  The panelists explored the pressing policy issues which could have a significant impact on the industry, from the creation of a pathway for the approval of follow-on biologics, patent reform, comparative effectiveness and the implementation of the Food and Drug Administration Amendments Act (FDAAA) which was signed into law last year.  The panelists also discussed Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags:

Elusive Cancer Endpoints: How to Survive the Uncertainty

The debate surrounding cancer endpoints has focused on the issue of quality of life and progression. Panelists shared some of the challenges in assessing quality of life, since it can be a fickle and subjective process. The data can be hard to nail down since patients don’t always fill out the forms. The critical issues include survival rates, improved quality of life and progression of disease. Everything must be taken into consideration to determine endpoints, which is why Read More >

Health  |  Leave a comment  |  Email This Post
Tags:

Diabetes: New Mechanisms, New Opportunities

Panelists in the diabetes panel stressed the importance of the growing prevalence of the disease – it’s expected to more than double by 2030. Those are big numbers, particularly because diabetes is the number one cause of preventable blindness. There is a light on the horizon – several new treatments for both Type 1 and Type 2 diabetes: XOMA – two current trials for Type 2 diabetes. XOMA’s drug could be administered once a month Read More >

Health  |  Leave a comment  |  Email This Post
Tags: